The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Share News (TILS)

  • There is currently no data for TILS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Tiziana Life Sciences Settles Fee; Director Zambeletti Departs

Wed, 20th Nov 2019 13:02

(Alliance News) - Tiziana Life Sciences PLC on Wednesday announced the departure of a director and the issue of shares in order to satisfy an GBP82,000 consultancy fee.

The London-headquartered biotechnology firm said Leopoldo Zambeletti has resigned as a non-executive officer.

"The company notes the significant business interests of Mr Zambeletti in a wide range of life sciences companies and expresses its gratitude for Mr Zambeletti's contribution to the company during his tenure," said Tiziana.

Further, the company has issued 190,698 shares at a price of 43 pence each to satisfy a GBP82,000 consultancy fee, without saying to whom it was paying the fee.

Following this, Tiziana will have 136.7 million shares in issue.

Shares in Tiziana were untraded at 41.00p in London on Wednesday during midday trading.

By Anna Farley; annafarley@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News
4 Dec 2019 15:38

Tiziana initiates study of 'Foralumab' in coated capsule form

(Sharecast News) - Clinical-stage biotechnology company Tiziana Life Sciences announced the initiation of a phase 1 clinical trial in healthy volunteers on Wednesday, with a proprietary oral formulation of 'Foralumab' encapsulated in enteric-coated capsules.

Read more
4 Dec 2019 11:52

Tiziana Life Sciences Kicks Off Oral Trials Of Antibody Foralumab

Tiziana Life Sciences Kicks Off Oral Trials Of Antibody Foralumab

Read more
1 Nov 2019 17:31

Tiziana Life Sciences Issues GBP1.4 Million Convertible Loan Notes

Tiziana Life Sciences Issues GBP1.4 Million Convertible Loan Notes

Read more
30 Sep 2019 10:27

Tiziana Loss Narrows In "Busy" First Half, Looks To Advance Drug Tests

Tiziana Loss Narrows In "Busy" First Half, Looks To Advance Drug Tests

Read more
16 Sep 2019 13:03

Tiziana Life Sciences Gets New Foralumab Formulation US Trial Approval

(Alliance News) - Tiziana Life Sciences PLC on Monday said the US Food & Drug Adminsitration has allowed the company to begin a phase 1 clinical trial of its novel Foralumab formulation in in

Read more
10 Sep 2019 14:34

Tiziana Life Sciences Announces Positive Data From Foralumab Trial

(Alliance News) - Tiziana Life Sciences PLC on Tuesday said data from its phase 1 trial of Foralumab showed the drug "was well-tolerated at all doses" and produced a positive biomarker a

Read more
4 Sep 2019 11:04

Encouraging Data From Tiziana Life Sciences Milciclib Cancer Study

(Alliance News) - Tiziana Life Sciences PLC on Wednesday announced positive data from its study of Milciclib in patients with advanced liver cancer.Shares in Tiziana were up 19% at 57.00 in

Read more
22 Jul 2019 09:54

Tiziana Reports No Drug-Related Deaths In Milciclib Liver Cancer trial

(Alliance News) - Tiziana Life Sciences PLC on Monday said there were no drug related deaths in its phase 2a trial of Milciclib in advanced liver cancer and the drug was well tolerated with some 6

Read more
1 Jul 2019 10:49

WINNERS & LOSERS SUMMARY: Future Rises After Positive Annual Outlook

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------DS Smith,

Read more
1 Jul 2019 10:20

Tiziana Notes Positive Study Of Drug Similar To Foralumab In Diabetes

(Alliance News) - Tiziana Life Sciences PLC on Monday noted a study in which a drug similar to Foralumab was shown to delay the onset of type-1 diabetes.Shares in the biotechnology company

Read more
1 May 2019 10:08

FDA asks Tiziana for more information on next 'foralumab' trial

(Sharecast News) - Biotechnology company Tiziana Life Sciences updated the market in its 'Investigational New Drug' (IND) application to the US Food and Drug Administration (FDA) on Wednesday, to initiate a phase 1 clinical trial of enteric-coated capsules of its 'foralumab' product in healthy volunteers.

Read more
24 Apr 2019 12:20

Most Patients Stick With Milciclib In Tiziana Life Sciences Study

LONDON (Alliance News) - Tiziana Life Sciences PLC on Wednesday reported encouraging interim data from its trial of milciclib in patients with advanced liver cancer.Shares in Tiziana were -

Read more
4 Apr 2019 10:58

Tiziana Life Sciences Annual Loss Narrows On Marginally Reduced Costs

LONDON (Alliance News) - Tiziana Life Sciences PLC on Thursday reported a slight reduction in its annual loss as costs were reduced.For 2018, the clinical stage biotechnology company posted

Read more
20 Mar 2019 13:01

Tiziana Life Sciences Submits Application For Foralumab Trial In US

LONDON (Alliance News) - Tiziana Life Sciences PLC on Wednesday said it has submitted an application in the US to begin a phase one trial of its autoimmune and inflammatory disease drug new drug a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.